Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E Cagni, Marzia Caproni, Carlo G Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V Di Brizzi, Valentina Dini, Francesca M Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V Marzano, Matteo Megna, Santo R Mercuri, Maria L Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
PURPOSE: Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight. MATERIALS AND METHODS: Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis...
December 2024: Journal of Dermatological Treatment